The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258%

It hasn't been the best quarter for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, since the share price has fallen 19% in that time. But that doesn't change the fact that shareholders have received really good returns over the last five years. We think most investors would be happy with the 258% return, over that period. So while it's never fun to see a share price fall, it's important to look at a longer time horizon. The more important question is whether the stock is too cheap or too expensive today.

The past week has proven to be lucrative for IDEAYA Biosciences investors, so let's see if fundamentals drove the company's five-year performance.

See our latest analysis for IDEAYA Biosciences

IDEAYA Biosciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 5 years IDEAYA Biosciences saw its revenue grow at 18% per year. That's well above most pre-profit companies. So it's not entirely surprising that the share price reflected this performance by increasing at a rate of 29% per year, in that time. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes IDEAYA Biosciences worth investigating - it may have its best days ahead.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

IDEAYA Biosciences is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. You can see what analysts are predicting for IDEAYA Biosciences in this interactive graph of future profit estimates.

A Different Perspective

IDEAYA Biosciences shareholders are down 1.6% for the year, but the market itself is up 37%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 29% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 3 warning signs we've spotted with IDEAYA Biosciences .

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.